Ying Cheng

机构：University of Science and Technology of China, Soochow University, Jilin Province Tumor Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Hefei First People's Hospital · ORCID：0000-0002-7185-4252

发表论文 82 篇 · 总被引 973 次 · h-index 19

代表论文

• Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (2024 · JAMA Oncology · 被引 62)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• USP14 modulates cell pyroptosis and ameliorates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing SIRT3 (2024 · Free Radical Biology and Medicine · 被引 10)
• Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors. (2025 · Journal of Clinical Oncology · 被引 5)
• First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma. (2025 · Journal of Clinical Oncology · 被引 5)